LDS/Medical Tests/Nucleophosmin (NPM1) Gene Mutation Analysis

Nucleophosmin (NPM1) Gene Mutation Analysis

The NPM1 gene is located at chromosome 5q35 and contains 12 exons. It encodes for nucleophosmin (NPM) which is also known as nucleolar phosphoprotein B23 also known as numatrin. Nucleophosmin is a 37 kDa nucleolar chaperone protein that shuttles between the nucleus and cytoplasm. It is an abundant nucleolar protein found in the nuclei of proliferating cells. In the nucleolus, nucleophosmin attaches to a tumor suppressor protein called alternative reading frame (ARF), keeping it in the proper location and protecting it from being broken down. NPM1 has diverse roles in ribosome biogenesis, mRNA processing, chromatin remodeling, embryogenesis, regulation of apoptosis and maintenance of genome stability.

Mutations in NPM1 gene is found approximately in 35% of adult and 8% in children with primary acute myeloid leukemia (AML). Mutations of NPM1 typically produces C-terminus changes that result in abnormal cytoplasmic localization of nucleophosmin. Since NPM1 is thought to have a tumor-suppressor function, alterations in its subcellular localization from the nucleus to the cytoplasm may be crucial for malignant transformation. Due to the interaction of ARF protein with the altered nucleophosmin, the tumor suppressor function of the ARF protein is reduced and leads to the uncontrolled production of abnormal white blood cells that occurs in AML. About 60%–80% of AML patients carrying a mutant NPM1 gene may have a normal karyotype. AML having mutated NPM1 and a normal karyotype may have favorable prognosis. Conversely, AML with both an NPM1 mutation and a FLT3-ITD mutation confers a poor prognosis.

  • As a prognostic indicator in patients with newly diagnosed AML
  • Disease management and therapy monitoring
NPM1 mutation is seen in approximately 30% of acute myeloid leukemia (AML) patients. It is prevalent in normal karyotype AML and frequently associated with FLT3 gene mutations.

Negative for mutations analyzed (No pathogenic variant or mutation detected)

PCR amplification with fluorescently labeled primers and capillary electrophoresis-based fragment analysis, next-generation sequencing (NGS).

Whole Blood (EDTA), Bone Marrow.

Stability

  • Ambient: 3-5 days
  • Refrigerated: 7-14 days
  • Frozen: Unacceptable
FLT3 gene mutation analysis, bone marrow aspiration, complete blood count (CBC), phenotypging by flow cytometry, Chromosome analysis.
1-2 weeks.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Nat Genet. 2019;51: 1518-1529. [PMID: 31570891]
  • N Engl J Med. 2016;374: 422-33. [PMID: 26789727]
  • Haematologica. 2007;92: 519-32. [PMID: 17488663]
  • Nature. 2005;437: 147-53. [PMID: 16007073]
  • Genetics Home Reference. Available at: https://ghr.nlm.nih.gov/gene/NPM1#
  • Molecular diagnostics techniques and applications for the clinical laboratory. In; chapter 21, molecular diagnostics of hematopoietic disorders. 2010, 243-260.